Optimus Drugs
Optimus Drugs, also known as Optimus Pharma, is a prominent player in the pharmaceutical industry, headquartered in India. Established in 2004, the company has made significant strides in the development and manufacturing of high-quality generic medications, catering to both domestic and international markets. With a strong operational presence across various regions, Optimus Drugs focuses on therapeutic areas such as oncology, cardiology, and neurology. The company is renowned for its commitment to innovation and quality, offering a diverse portfolio of products that includes formulations and active pharmaceutical ingredients (APIs). Optimus Drugs has achieved notable recognition for its adherence to stringent regulatory standards, positioning itself as a trusted supplier in the global pharmaceutical landscape. With a dedication to improving patient outcomes, Optimus Drugs continues to expand its reach and impact within the healthcare sector.
DitchCarbon Score
How does Optimus Drugs's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Optimus Drugs's score of 29 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Optimus Drugs's reported carbon emissions
In 2023, Optimus Drugs reported total carbon emissions of approximately 37,724,000 kg CO2e, comprising 10,057,000 kg CO2e from Scope 1 and 17,302,000 kg CO2e from Scope 2 emissions. For the following year, 2024, emissions decreased significantly to about 2,320,000 kg CO2e, with Scope 1 emissions at 789,000 kg CO2e and Scope 2 emissions at 1,332,000 kg CO2e. Optimus Drugs has set an ambitious target to reduce emission intensity by 62% by 2030, using 2023 as the baseline year. The company is committed to reporting its emissions data annually and has indicated that it is on track to meet these reduction targets. This commitment reflects a proactive approach to addressing climate change and reducing its overall carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 10,057,000 | 000,000 |
| Scope 2 | 17,302,000 | 0,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Optimus Drugs is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
